A Study on the Effectiveness of Musculoskeletal Corticosteroid Injections for Reducing Patient Symptom Scores in Primary Care Practice.

IF 1.5 Q3 RHEUMATOLOGY

Musculoskeletal Care Pub Date : 2024-09-01 DOI:10.1002/msc.1933

Abigail Harmer, John Ribchester, Inderpal Malhi, Brad Robinson, Nosa Eguakun

{"title":"A Study on the Effectiveness of Musculoskeletal Corticosteroid Injections for Reducing Patient Symptom Scores in Primary Care Practice.","authors":"Abigail Harmer, John Ribchester, Inderpal Malhi, Brad Robinson, Nosa Eguakun","doi":"10.1002/msc.1933","DOIUrl":null,"url":null,"abstract":"Objectives: To present data on the effectiveness of corticosteroid injections (CSI) in reducing symptom scores for musculoskeletal conditions in patients treated in an NHS primary care CSI service. The data will also examine whether adding local anaesthetic to the corticosteroid preparation affects the overall patient outcomes in symptom scores.Methods: A Patient-reported outcomes (PRO) questionnaire was used to collect data. Patients were asked to complete the questionnaire post-CSI. Patients were asked to rate their symptoms on a score of 0-6 before and after their injection. Data were calculated using standard deviation and paired t-test to assess the effectiveness of CSI in reducing symptom scores.Results: Overall, 172 patients (79.6%) reported an improvement in symptomatology post CSI. Improvements were seen across all injection sites. Of those taking medication for their symptoms, 73 patients (55.7%) reported that they were able to reduce their medication. Data did not suggest that adding local anaesthetic to the injectate resulted in better patient outcomes. Post-injection symptom scores were statistically similar across all clinicians.Conclusion: 83.7% of patients experienced a reduction in symptom scores post injection. Adding lidocaine to the injectate preparation did not result in any statistically significant improvement in patient outcome. Over half of the participants were able to reduce their medication post injection, which demonstrates this is a highly effective primary care service for treatment/management of some MSK conditions.","PeriodicalId":46945,"journal":{"name":"Musculoskeletal Care","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Musculoskeletal Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/msc.1933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To present data on the effectiveness of corticosteroid injections (CSI) in reducing symptom scores for musculoskeletal conditions in patients treated in an NHS primary care CSI service. The data will also examine whether adding local anaesthetic to the corticosteroid preparation affects the overall patient outcomes in symptom scores.

Methods: A Patient-reported outcomes (PRO) questionnaire was used to collect data. Patients were asked to complete the questionnaire post-CSI. Patients were asked to rate their symptoms on a score of 0-6 before and after their injection. Data were calculated using standard deviation and paired t-test to assess the effectiveness of CSI in reducing symptom scores.

Results: Overall, 172 patients (79.6%) reported an improvement in symptomatology post CSI. Improvements were seen across all injection sites. Of those taking medication for their symptoms, 73 patients (55.7%) reported that they were able to reduce their medication. Data did not suggest that adding local anaesthetic to the injectate resulted in better patient outcomes. Post-injection symptom scores were statistically similar across all clinicians.

Conclusion: 83.7% of patients experienced a reduction in symptom scores post injection. Adding lidocaine to the injectate preparation did not result in any statistically significant improvement in patient outcome. Over half of the participants were able to reduce their medication post injection, which demonstrates this is a highly effective primary care service for treatment/management of some MSK conditions.

查看原文本刊更多论文

关于肌肉骨骼类皮质激素注射在初级医疗实践中降低患者症状评分效果的研究。

目的：提供关于皮质类固醇注射（CSI）在降低肌肉骨骼疾病症状评分方面的有效性数据，这些患者均接受过英国国家医疗服务体系初级医疗CSI服务的治疗。这些数据还将检验在皮质类固醇制剂中加入局麻药是否会影响患者症状评分的总体结果：方法：采用患者报告结果 (PRO) 问卷收集数据。患者被要求在CSI后填写问卷。要求患者对注射前后的症状进行评分，评分标准为 0-6 分。使用标准差和配对 t 检验计算数据，以评估 CSI 在减少症状评分方面的效果：总的来说，172 名患者（79.6%）在 CSI 后症状有所改善。所有注射部位的症状都有所改善。在服用药物治疗症状的患者中，有 73 名患者（55.7%）表示能够减少用药。数据并未显示在注射剂中添加局麻药会带来更好的疗效。结论：83.7% 的患者在注射后症状减轻。结论：83.7% 的患者在注射后症状评分有所减轻，在注射剂中添加利多卡因并不会对患者的治疗效果产生任何统计学意义上的显著改善。超过半数的参与者在注射后能够减少用药，这表明这是一种治疗/管理某些 MSK 病症的高效初级保健服务。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Musculoskeletal Care RHEUMATOLOGY-

CiteScore

2.30

自引率

7.70%

发文量

期刊介绍： Musculoskeletal Care is a peer-reviewed journal for all health professionals committed to the clinical delivery of high quality care for people with musculoskeletal conditions and providing knowledge to support decision making by professionals, patients and policy makers. This journal publishes papers on original research, applied research, review articles and clinical guidelines. Regular topics include patient education, psychological and social impact, patient experiences of health care, clinical up dates and the effectiveness of therapy.